Academics today, around the world, are confined by the way their research output is measured. Indicators that count the ...

Posts from this author will be added to your daily email digest and your homepage feed. is a NYC-based AI reporter and is currently supported by the Tarbell Center for AI Journalism. She covers AI ...

Picking her new name led Tess Tanenbaum to ponder many questions. Am I Josie or a Hanna? Should it sound similar to her previous masculine name? What will it look like as a signature? She began to ...

Deciphering ancient texts with modern tools, Michael Langlois challenges what we know about the Dead Sea Scrolls A copy of a Greek inscription, made by laying wet paper or plaster over carved stone to ...

Scholar Rock Holding Corporation's lead candidate, apitegromab, has shown promising efficacy in treating SMA and is awaiting FDA and EMA approval, with a potential market launch by late 2025.

Scholar Rock Holding Corporation announced third-quarter 2025 results, reporting a US$102.22 million net loss and highlighted plans to resubmit the biologics license application for apitegromab ...

Scholar Rock Holding (SRRK) is back in focus after updating investors on an FDA warning letter sent to its manufacturing partner, the Novo Nordisk Bloomington, Indiana site (formerly Catalent Indiana ...